loader2
Login Open ICICI 3-in-1 Account
  • Text Size
  • Text to Speech
  • Color Contrast
  • Pause Animations
Open ICICI 3-in-1 Account

Aurobindo Pharma Results: Latest Quarterly Results & Analysis

Open Free Trading Account Online with ICICIDIRECT
+91
Aurobindo Pharma Ltd. 06 Aug 2026 12:24 PM
Result PDF

Q1FY27 Quarterly Result Announced for Aurobindo Pharma Ltd.

Pharmaceuticals company Aurobindo Pharma announced Q1FY27 results

Consolidated Financial Highlights:

  • Revenue from Operations: Stood at Rs 91,503.5 million, representing a YoY growth of 16.3% compared to Rs 78,681.4 million in Q1FY26 and a QoQ increase of 3.35% from Rs 88,533.4 million in Q4FY26.
  • Total Income: Reached Rs 94,145.8 million, up 18.08% YoY from Rs 79,734.4 million and up 4.95% QoQ from Rs 89,703.8 million.
  • Profit Before Tax (PBT): Reported at Rs 15,150.9 million, an increase of 25.55% YoY from Rs 12,068.0 million and a growth of 17.4% QoQ from Rs 12,906.1 million.
  • Profit After Tax (PAT): Net profit attributable to owners of the parent company was Rs 10,325.6 million, marking a YoY growth of 25.2% from Rs 8,247.5 million and a QoQ growth of 12.08% from Rs 9,212.6 million.
  • Earnings Per Share (EPS): Basic and diluted EPS stood at Rs 17.86 for the quarter, compared to Rs 14.20 in Q1FY26 and Rs 15.86 in Q4FY26.

Standalone Financial Highlights:

  • Revenue from Operations: Stood at Rs 27,995.1 million, reflecting a YoY decline of 1.71% from Rs 28,481.7 million, but a marginal QoQ increase of 0.47% from Rs 27,865.5 million in Q4FY26.
  • Total Income: Reached Rs 30,414.0 million, up 3.73% YoY from Rs 29,319.4 million and up 1.36% QoQ from Rs 30,006.4 million.
  • Profit Before Tax (PBT): Reported at Rs 10,080.8 million, an increase of 34.39% YoY from Rs 7,500.9 million and a growth of 15.04% QoQ from Rs 8,763.1 million.
  • Profit After Tax (PAT): Net profit for the quarter was Rs 7,372.2 million, up 31.85% YoY from Rs 5,591.3 million and up 6.5% QoQ from Rs 6,922.3 million.

Business Highlights:

  • US Revenue: Increased by 8.1% YoY to Rs 37,700 million, primarily driven by volume gains and new launches, and grew 6.4% QoQ from Rs 35,430 million.
  • Europe Revenue: Grew significantly by 25.6% YoY to Rs 29,370 million, accounting for 32.1% of consolidated revenue, and grew 5.1% QoQ from Rs 27,950 million.
  • Growth Markets Revenue: Saw a robust growth of 37.7% YoY to Rs 10,630 million and an 8.5% QoQ increase from Rs 9,800 million.
  • ARV Revenue: Stood at Rs 3,300 million, a YoY decrease of 6.9% but a marginal QoQ increase of 0.8% compared to Q4FY26.
  • Active Pharmaceutical Ingredients (API) Revenue: Grew by 14.6% YoY to Rs 10,490 million, although it saw a sequential QoQ decline of 13.1% from Rs 12,080 million due to seasonal softness in the antibiotics portfolio.
  • Acquisitions & Buyback: The company completed the acquisition of 100% membership interest in Lannett Company LLC on June 29, 2026. Additionally, the company approved a buyback of equity shares for an aggregate value not exceeding Rs 8,000 million.
  • Product Approvals: Received final approval for 10 products from USFDA during the quarter.
  • Cash Flow: Generated free cash flow of USD 98 million during the quarter.

K. Nithyananda Reddy, Vice-Chairman and Managing Director of the Company, said: “We have commenced FY27 on a strong note, delivering healthy growth across our businesses through disciplined execution, operational excellence, and the continued strength of our diversified product portfolio. While the global operating environment remains dynamic, our resilient business model, expanding capabilities, and strategic investments position us well to achieve our long-term growth objectives and create sustained value for our stakeholders.”

Result PDF

Result PDF

Pharmaceuticals company Aurobindo Pharma announced Q4FY26 & FY26 results

Standalone Financial Highlights:

  • Total Revenue from Operations:
    • Q4FY26: Rs 27,865.5 million, compared to Rs 27,472.8 million in Q3FY26 (QoQ increase of 1.43%) and Rs 27,319.9 million in Q4FY25 (YoY increase of 2.00%).
    • FY26: Rs 1,11,717.2 million, compared to Rs 1,09,333.0 million in FY25 (YoY increase of 2.18%).
  • Total Income:
    • Q4FY26: Rs 30,006.4 million, compared to Rs 28,774.3 million in Q3FY26 (QoQ increase of 4.28%) and Rs 28,459.7 million in Q4FY25 (YoY increase of 5.43%).
    • FY26: Rs 1,17,592.5 million, compared to Rs 1,12,614.2 million in FY25 (YoY increase of 4.42%).
  • Profit After Tax (PAT):
    • Q4FY26: Rs 6,922.3 million, compared to Rs 5,820.7 million in Q3FY26 (QoQ increase of 18.93%) and Rs 4,081.7 million in Q4FY25 (YoY increase of 69.60%).
    • FY26: Rs 24,148.0 million, compared to Rs 17,467.9 million in FY25 (YoY increase of 38.24%).

Consolidated Financial Highlights:

  • Total Revenue from Operations:
    • Q4FY26: Rs 88,533.4 million, compared to Rs 86,459.0 million in Q3FY26 (QoQ increase of 2.40%) and Rs 83,821.2 million in Q4FY25 (YoY increase of 5.62%).
    • FY26: Rs 3,36,530.8 million, compared to Rs 3,17,237.3 million in FY25 (YoY increase of 6.08%).
  • Total Income:
    • Q4FY26: Rs 89,703.8 million, compared to Rs 88,335.4 million in Q3FY26 (QoQ increase of 1.55%) and Rs 85,169.3 million in Q4FY25 (YoY increase of 5.32%).
    • FY26: Rs 3,41,451.7 million, compared to Rs 3,23,455.8 million in FY25 (YoY increase of 5.56%).
  • Profit After Tax (PAT):
    • Q4FY26: Rs 9,208.4 million, compared to Rs 9,098.0 million in Q3FY26 (QoQ increase of 1.21%) and Rs 9,028.3 million in Q4FY25 (YoY increase of 1.99%).
    • FY26: Rs 35,029.7 million, compared to Rs 34,835.7 million in FY25 (YoY increase of 0.56%).

Business Highlights:

  • Segment Reporting: The company operates in only one reportable segment, 'Pharmaceuticals', in accordance with Ind AS 108, "Operating Segment".
  • Corporate Developments:
    • The Board of Directors approved a buyback of 5,423,728 fully paid-up equity shares of face value of Rs 1 each for an aggregate value not exceeding Rs 8,000.0 million on April 06, 2026. This was paid to eligible shareholders on May 07, 2026.
    • The domestic branded generic pharmaceutical formulations business was transferred to Auropharm Limited (a wholly-owned subsidiary) on a going concern basis via a slump sale effective April 01, 2026.
    • Effective January 01, 2026, Auropharm Limited acquired the non-oncology prescription formulations business from M/s Khandelwal Laboratories Private Limited for a total consideration of Rs 3,250 million.
  • Labour Codes Impact: The company recognized an incremental gratuity and leave liability aggregating to Rs 173.8 million in the Standalone financial results and Rs 653.3 million in the Consolidated financial results for the quarter ended December 31, 2025 and year ended March 31, 2026, due to the notification of Labour Codes. This has been presented as "Exceptional Items"

K. Nithyananda Reddy, Vice-Chairman & Managing Director, said: “We are encouraged by our performance for the quarter and the year, reflecting the resilience of our business model and the strength of our extensive product portfolio. Consistent volumes coupled with improved operating efficiencies, and disciplined execution have contributed positively to our results. With ongoing investments in capacity expansion and the stabilization of recently commercialized facilities, we remain confident in our ability to support sustainable growth and create long-term value for our stakeholders.”

Result PDF

Pharmaceuticals company Aurobindo Pharma announced Q3FY26 results

  • Revenue from Operations increased by 8.4% YoY to Rs 8,646 crore with growth in Europe and ARV.
  • US formulations revenue increased by 2.2% YoY to Rs 3,739 crore (USD 420 million).
  • Europe formulations revenue increased by 27.4% YoY to Rs 2,703 crore (EUR 261 million).
  • Growth Markets revenue remained flat YoY at Rs 865 crore (USD 97 million).
  • ARV revenue increased by 22.4% YoY to Rs 376 crore (USD 42 million).
  • EBITDA before R&D stood at Rs 2,163 crores with a margin of 25.0%.
  • EBITDA before Forex and Other Income stood at Rs 1,773 crore; EBITDA margin at 20.5%.
  • Research & Development (R&D, including depreciation) spend was Rs 409 crore, 4.7% of revenues.
  • Received final approval for 7 ANDAs from the USFDA (including 2 ANDAs previously tentatively approved, now receiving final approval).
  • Net Profit for the period stood at Rs 910 crore. (inclusive of one-time cost due to change in labour code of Rs 65 crore).
  • Strong net cash position as on 31-Dec-25 after appropriating cash for the acquisition of Khandelwal laboratories is at USD 251 million.
  • Free Cashflows of USD 118 million generated during the quarter • Basic & Diluted EPS stood at Rs 15.67 per share.

K. Nithyananda Reddy, Vice-Chairman & Managing Director, said: “Q3 reflected steady execution across Aurobindo’s core businesses, supported by stable demand and the strength of our diversified product portfolio in key markets, including the U.S. and Europe. Growth remained measured, with continued focus on operational discipline and a balanced approach to growth and profitability. As we progress our strategic initiatives, we remain cautious yet confident in our ability to support sustainable value creation over the medium term.”

Result PDF

Pharmaceuticals company Aurobindo Pharma announced Q3FY25 results

  • Revenue from Operations increased by 8.5% YoY to Rs 7,979 crore with growth across the businesses.
  • US formulations revenue decreased by 2.3% YoY to Rs 3,671 crore (USD 435 million).
  • Europe formulations revenue increased by 22.7% YoY to Rs 2,121 crore (EUR 236 million).
  • Growth Markets revenue increased by 39.3% YoY to Rs 873 crore (USD 104 million).
  • ARV revenue increased by 71.2% YoY to Rs 307 crore (USD 36 million).
  • API revenue decreased by 1.6% YoY to Rs 1,006 crore (USD 119 million).
  • EBITDA before R&D stood at Rs 2,056 crores with a margin of 25.8%.
  • EBITDA before Forex and Other Income stood at Rs 1,628 crore; EBITDA margin at 20.4%.
  • Research & Development (R&D including depreciation) spend was Rs 450 crore, 5.6% of revenue.
  • Received final approval for 8 ANDAs (including 1 ANDA previously tentatively approved, now received the final approval) from the USFDA.
  • Net Profit for the period stood at Rs 846 crore.
  • Basic & Diluted EPS stood at Rs 14.56 per share.

Nithyananda Reddy, Vice-Chairman and Managing Director, said: " We are pleased to report our highest-ever quarterly revenue, driven by volume growth from our diverse and expanding product portfolio coupled with new launches. This performance highlights our resilience. Looking ahead, we are enhancing our manufacturing capabilities and ramping up our specialty and injectable business. With these initiatives, we expect notable profitability improvements and are well-positioned to sustain growth and meet our objectives for the year."

Result PDF

Pharmaceuticals company Aurobindo Pharma announced Q2FY25 results

  • Revenue from Operations increased by 8.0% YoY to Rs 7,796 crore with growth across the businesses.
  • US formulations (excluding Puerto Rico) revenue increased by 4.3% YoY to Rs 3,530 crore (USD 421 million).
  • Europe formulations revenue increased by 19.0% YoY to Rs 2,105 crore (EUR 229 million).
  • Growth Markets revenue increased by 44.0% YoY to Rs 812 crore (USD 97 million).
  • ARV revenue decreased by 22.8% YoY to Rs 193 crore (USD 23 million).
  • API revenue remained flat YoY at Rs 1,156 crore (USD 138 million).
  • EBITDA before R&D stood at Rs 1,954 crores with a margin of 25.1%.
  • EBITDA before Forex and Other Income stood at Rs 1,566 crore; EBITDA margin at 20.1%.
  • Research & Development (R&D including depreciation) spend was Rs 410 crore, 5.3% of revenues.
  • Received final approval for 8 ANDAs including from the USFDA.
  • Net Profit for the period stood at Rs 817 crore, vs. Rs 752 crore in Q2FY24.
  • Basic & Diluted EPS grew by 9.1% YoY to Rs 14.00 per share

K. Nithyananda Reddy, Vice-Chairman and Managing Director, Aurobindo Pharma, said: "We are pleased with the continued growth in revenues across our key business areas this quarter, reflecting the resilience of our diversified portfolio. While profitability saw a slight dip, primarily due to the transient nature of certain business activities, our underlying performance remains strong. With a solid foundation and ongoing operational improvements, we are confident of maintaining our growth trajectory and achieving our strategic objectives for the year."

Result PDF

Pharmaceuticals company Aurobindo Pharma announced Q1FY25 results: 

  • Revenue from Operations increased by 10.5% YoY to Rs 7,567 crore with growth across the businesses
  • US formulations (excluding Puerto Rico) revenue increased by 13.3% YoY to Rs 3,555 crore (USD 426 million)
  • Europe formulations revenue increased by 7.9% YoY to Rs 1,982 crore (EUR 221 million)
  • Growth Markets revenue increased by 49.2% YoY to Rs 709 crore (USD 85 million)
  • ARV revenue increased by 13.9% YoY to Rs 229 crore (USD 27 million)
  • API revenue grew by 5.6% YoY to Rs 1,092 crore (USD 131 million)
  • EBITDA before Forex and Other Income stood at Rs 1,620 crore; EBITDA margin at 21.4%
  • Research & Development (R&D) spend was Rs 339 crore, 4.5% of revenues
  • Received final approval for 10 ANDAs including 1 Specialty & Injectable product from the USFDA
  • Net Profit after Share of Profit/Loss of JV and Minority Interest at Rs 919 crore, vs. Rs 571 crore in Q1FY24
  • Basic & Diluted EPS grew by 61.4% YoY to Rs 15.69 per share

Commenting on the Company’s performance, K. Nithyananda Reddy, Vice-Chairman and Managing Director of the Company said: “We are pleased with our continued strong performance this quarter, with a significant top-line growth across all our business segments. Our profitability was sustained by improved gross margins and operational efficiencies, while ramping-up our recently commercialized plants. We are confident in our ability to achieve our growth targets for FY25.”

Result PDF

Pharmaceuticals company Aurobindo Pharma announced Q4FY24 results:

  • Revenue from Operations increased by 17.1% YoY to Rs 7,580 crore with growth across the businesses
  • US formulations (excluding Puerto Rico) revenue increased by 21.6% YoY to Rs 3,588 crore (USD 432 million)
  • Europe formulation revenue increased by 10.4% YoY to Rs 1,832 crore (EUR 203 million)
  • Growth Markets revenue increased by 49.5% YoY to Rs 852 crore (USD 103 million)
  • ARV revenue increased by 31.5% YoY to Rs 238 crore (USD 29 million)
  • API revenue remained flat YoY at Rs 1,019 crore (USD 123 million)
  • EBITDA before Forex and Other income stood at Rs 1,687 crore; EBITDA margin of 22.3%
  • Research & Development (R&D) spend stood at Rs 392 crore, 5.2% of revenues (vs. Q3 FY24: 5.4%)
  • Received final approval for 17 ANDAs including 4 specialty & injectable products from the USFDA
  • Net Profit after Share of Profit/Loss of JV and minority interest at Rs 909 crore, vs. Rs 506 crore in Q4FY23
  • Basic & Diluted EPS grew by 79.5% YoY to Rs 15.51 per share

Commenting on the Company’s performance, K. Nithyananda Reddy, Vice-Chairman and Managing Director of the Company said: “We are extremely delighted to report a strong performance for the quarter and the year, supported by the expansion into the new markets, product launches and stable pricing. Our improved capacity utilization has led to higher operating efficiencies. We are confident of continuing our growth in the upcoming year, while stabilizing the operations of the recently commercialized facilities.”

Result PDF

Pharmaceuticals company Aurobindo Pharma announced Q3FY24 results:

  • Revenue from Operations increased by 14.7% YoY to Rs 7,352 crore with growth seen across multiple businesses.
  • US formulations (excluding Puerto Rico) revenue increased by 28.9% YoY to Rs 3,756 crore (USD 451 million).
  • Europe formulation revenue increased by 1.6% YoY to Rs 1,728 crore (EUR 193 million).
  • Growth Markets revenue increased by 25.6% YoY to Rs 627 crore (USD 75 million).
  • ARV revenue decreased by 28.6% YoY to Rs 179 crore (USD 22 million).
  • API revenue grew by 7.1% YoY to Rs 1,022 crore (USD 123 million).
  • EBITDA before Forex and Other income stood at Rs 1,601 crore; EBITDA margin of 21.8%.
  • Research & Development (R&D) spend stood at Rs 398 crore, 5.4% of revenues (vs. Q2 FY24: 4.2%).
  • Received final approval for 16 ANDAs including 7 specialty & injectable products from the USFDA.
  • Net Profit after Share of Profit/Loss of JV and minority interest at Rs 936 crore, vs. Rs 491 crore in Q3FY23.
  • Basic & Diluted EPS grew by 91.4% YoY to Rs 16.04 per share.
  • Board has approved interim dividend @ 150% i.e. Rs 1.5 per equity share of Rs 1/- for FY24.

Commenting on the Company’s performance, K. Nithyananda Reddy, Vice-Chairman and Managing Director of the Company said: “We are very pleased with the considerable progress we have made in our operations, and the cost efficiencies we have achieved, this quarter’s highest ever sales and EBITDA reflect the same. With our continued focus on developing a strong pipeline and driving the commercialization of our key projects, we are confident of our growth trajectory in the months ahead.”

Result PDF

Pharmaceutical company Aurobindo Pharma announced Q2FY24 results:

  • Revenue from operations increased by 25.8% YoY to Rs 7,219 crore with growth seen across key segments
  • US formulations (excluding Puerto Rico) revenue increased by 35.7% YoY to Rs 3,385 crore (USD 409 million)
  • Europe formulation revenue increased by 16.7% YoY to Rs 1,769 crore (EUR 197 million)
  • Growth markets revenue increased by 24.7% YoY to Rs 564 crore (USD 68 million)
  • ARV revenue increased by 52.1% YoY to Rs 250 crore (USD 30 million)
  • API revenue grew by 20.3% YoY to Rs 1,166 crore
  • EBITDA before Forex and Other income stood at Rs 1,403 crore; EBITDA margin of 19.4 %
  • Research & Development (R&D) spend stood at Rs 300 crore, 4.2% of revenues (vs. Q1 FY24: 5.7%)
  • Received final approval for 15 ANDAs including 3 injectable products from the USFDA
  • Net Profit after Share of Profit/Loss of JV and minority interest at Rs 752 crore, vs. Rs 409 crore in Q2FY23
  • Basic & Diluted EPS grew by 83.6% YoY to Rs 12.83 per share
  • Board has approved interim dividend at 300% i.e. Rs 3 per equity share of Re 1 for the year FY24

Commenting on the company’s performance, K. Nithyananda Reddy, Vice-Chairman and Managing Director of the Company said, “This is yet another quarter with highest ever sales, driven by robust performance across the markets, and continued margin expansion, aided by operational leverage and efficiencies. With our strong product pipeline, focus on compliance and key projects in advanced stages, we will continue our growth journey, while generating value for our stakeholders.”

 

Result PDF

Pharmaceuticals company Aurobindo Pharma announced Q1FY24 results:

  • Revenue from Operations at Rs 6,850.5 croreore increased by 9.9% YoY
  • US formulations revenue increased by 11.2% YoY to Rs 3,304 crore
  • Europe formulation revenue stood at Rs 1,837 crore, with an increase of 18.6% YoY
  • Growth Markets revenue grew by 12.9% YoY to Rs 486 crore
  • ARV revenue stood at Rs 190 crore
  • API revenue grew by 14.0% YoY to Rs 1,033 crore
  • EBITDA before Forex and Other income stood at Rs 1,151.4 crore; EBITDA margin for the quarter was 16.8%.
  • Research & Development (R&D) spend at Rs 387.6 crore, 5.7% of revenues (Q4FY23: 6.3%)
  • Received final approval for 19 ANDAs including 7 injectable products from the USFDA
  • Net Profit after Share of Profit/Loss of JV and minority interest stood at Rs 570.8 crore, as against Rs 520.5 crore in Q1FY23
  • Basic & Diluted EPS is Rs 9.74 per share

Commenting on the Company’s performance, K. Nithyananda Reddy, Vice-Chairman and Managing Director of the Company said, “We are pleased to start the new financial year on a good note with strong top-line growth and margin expansion aided by improved performance across our key markets. With our product pipeline continuing to advance, and execution of growth drivers proceeding as planned, we are confident that our fundamental strengths position us to create an upward trajectory. Looking ahead, we are confident in executing our growth initiatives and creating long-term value for our shareholders.”

 

 

Result PDF

Trending News

Newgen Software wins $1.79M Qatar deal for compliance platform

Newgen Software has executed an agreement with a Qatar-based customer for a total contract value of US$1.79mn (~₹17.14cr). 

Published on 22-Sep-2026 09:12

Patel Engineering Debt Cuts: ~7.2% Promoter Share Pledge Revoked

Patel Engineering Limited reported disclosures regarding the revocation and release of promoter share pledges totalling to ~7.2% of total equity of the company

Published on 22-Sep-2026 09:11

GRSE Approves ₹2,896 Cr for Greenfield Shipyard at Raichak

GRSE’s Board has approved a capital budgetary outlay of ₹2,896 crore for construction of a greenfield shipyard at Raichak, aimed at expanding the company’s shipbuilding capacity across both naval and commercial segments. 

Published on 22-Sep-2026 09:10

Motherson to Acquire 50.1% Stake in Rotary Connectors for ₹500 Cr

In a press release, Samvardhana Motherson International, through its wholly owned subsidiary Samvardhana Motherson Adsys Tech (SMAST), has approved the acquisition of a 50.1% stake in Rotary Connectors Pvt Ltd (RCPL) for an enterprise value of ₹500.4 crore in an all-cash transaction

Published on 22-Sep-2026 09:09

GST 2.0 Cuts Spark 29% Surge in Under-4m Auto Sales as First-Time Indian Car Buyers Return

According to media sources, First-time car buyers are making a strong comeback in India, with their share of passenger-vehicle sales rising by 10 percentage points as GST 2.0 has improved affordability for entry-level cars

Published on 22-Sep-2026 09:08

Nearly 38% of India's domestic coal plants hit critical stock lows as power demand surges

Nearly 38% (65/175) of domestic coal-based power plants in India were critically low on coal stocks as of September 20 2026. 

Published on 22-Sep-2026 09:07

Disclaimer – I ICICI Securities Ltd. ( I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is acting as a distributor to solicit bond related products. All disputes with respect to the distribution activity, would not have access to Exchange investor redressal forum or Arbitration mechanism. The contents herein above shall not be considered as an invitation or persuasion to trade or invest. I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. Investments in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein mentioned are solely for informational and educational purpose.
Download App

Download Our App

Get it on google Play Store Download on the App Store
market app